Acromegaly News and Research RSS Feed - Acromegaly News and Research

Acromegaly is a syndrome that results when the pituitary gland produces excess growth hormone (hGH) after epiphyseal plate closure at puberty.
ANP reports primary efficacy results from ATL1103 Phase II trial in patients with acromegaly

ANP reports primary efficacy results from ATL1103 Phase II trial in patients with acromegaly

Antisense Therapeutics Limited is pleased to report the primary efficacy results from its Phase II clinical trial of ATL1103 in patients with the potentially life threatening growth disorder, acromegaly. [More]
Acromegaly and antisense therapy: an interview with Mark Diamond, CEO Antisense Therapeutics

Acromegaly and antisense therapy: an interview with Mark Diamond, CEO Antisense Therapeutics

Acromegaly is a chronic, life-threatening disease triggered by a benign tumour of the pituitary gland causing excessive growth hormone release. Oversupply of growth hormone stimulates liver, fat and kidney cells to produce excess levels of Insulin-Like Growth Factor I (IGFI), which causes abnormal growth of the bones of the hands, face and feet and bodily organs. [More]
Glide Pharma announces successful completion of pre-clinical proof-of-concept study with novel solid formulation of octreotide acetate

Glide Pharma announces successful completion of pre-clinical proof-of-concept study with novel solid formulation of octreotide acetate

Glide Pharma, the pharmaceutical development and device company focused on solid dose formulations of therapeutics and vaccines, today announced that its novel solid formulation of octreotide acetate achieved successful results in a pre-clinical proof-of-concept study comparing it with the currently marketed liquid product (Sandostatin®). [More]
Ipsen’s Somatuline CLARINET Phase III study published online in NEJM

Ipsen’s Somatuline CLARINET Phase III study published online in NEJM

The U.S. affiliate of Ipsen today announced that the New England Journal of Medicine has published clinical trial results showing that Somatuline Autogel / Somatuline Depot (lanreotide) Injection 120 mg (referred to as Somatuline) achieved statistically significant prolongation of progression free survival (PFS) over placebo in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). [More]
Ipsen seeks marketing authorization from FDA for Somatuline Depot 120mg injection

Ipsen seeks marketing authorization from FDA for Somatuline Depot 120mg injection

Ipsen Biopharmaceuticals, Inc., the U.S. affiliate of Ipsen today announced that it has submitted a Supplemental New Drug Application to the U.S. Food and Drug Administration for Somatuline Depot 120mg injection for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). [More]
Ipsen submits Supplemental New Drug Application to FDA for Somatuline Depot 120mg injection

Ipsen submits Supplemental New Drug Application to FDA for Somatuline Depot 120mg injection

Ipsen today announced that it has submitted a Supplemental New Drug Application to the U.S. Food and Drug Administration for Somatuline Depot 120mg injection for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). [More]
Novartis presents Phase III results of Signifor LAR therapy in patients with acromegaly

Novartis presents Phase III results of Signifor LAR therapy in patients with acromegaly

Novartis today presented results from a pivotal Phase III trial of investigational therapy Signifor® LAR (pasireotide LAR; SOM230) in patients with acromegaly for whom current standard of care provides inadequate disease control. [More]
Antisense Therapeutics enrolls acromegalic patients in ATL1103 Phase II trial

Antisense Therapeutics enrolls acromegalic patients in ATL1103 Phase II trial

Antisense Therapeutics Limited is pleased to report that 24 acromegalic patients have been successfully enrolled and randomized to one of the two treatment regimens of dosing in the Phase II trial of ATL1103 for the growth disorder, acromegaly. This satisfies the necessary patient numbers proposed for the trial. [More]
Aradigm reports record revenue of $4.6M in fourth quarter 2013

Aradigm reports record revenue of $4.6M in fourth quarter 2013

Aradigm Corporation (the "Company") today announced financial results for the fourth quarter and full year ended December 31, 2013. [More]
ANP reports positive interim results from ATL1103 Phase II clinical trial for acromegaly

ANP reports positive interim results from ATL1103 Phase II clinical trial for acromegaly

Antisense Therapeutics Limited is pleased to advise that positive results have been achieved from the interim analysis of a subset of available data from its Phase II clinical trial of ATL1103 in patients with the growth disorder, acromegaly. [More]
Drugs often fail to bring acromegaly under control in routine clinical practice

Drugs often fail to bring acromegaly under control in routine clinical practice

Over a quarter of UK patients treated for growth hormone-producing tumours do not achieve 'safe' growth hormone levels, according to a 30 year UK multi-centre study of clinical management of the rare disease acromegaly. The findings by the Society for Endocrinology UK Acromegaly Register, published in the November issue of Clinical Endocrinology, show that drugs to control acromegaly often fail to bring the disease completely under control in routine clinical practice. [More]
Chiasma, Roche enter agreement to develop and commercialize Octreolin

Chiasma, Roche enter agreement to develop and commercialize Octreolin

Roche and Chiasma Inc., a privately held biopharma company, announced today that they have entered into an agreement to develop and commercialize Chiasma's proprietary product Octreolin, initially for acromegaly and subsequently for neuroendocrine tumors. [More]
FDA approves Novartis Signifor injection for treatment of Cushing's disease

FDA approves Novartis Signifor injection for treatment of Cushing's disease

Novartis announced today that the US Food and Drug Administration (FDA) has approved Signifor (pasireotide) injection for the treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative. [More]
FDA EMDAC votes unanimously in support of Signifor use for treatment of Cushing's disease

FDA EMDAC votes unanimously in support of Signifor use for treatment of Cushing's disease

The US Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) has voted unanimously in support of the use of Signifor (pasireotide) for the treatment of patients with Cushing's disease who require medical therapeutic intervention. [More]
New investment to fund Chiasma's Octreolin Phase 3 pivotal program for acromegaly

New investment to fund Chiasma's Octreolin Phase 3 pivotal program for acromegaly

Chiasma, Inc., a privately held biopharma company, announced that it closed a $38.5 million equity financing co-led by new investor Abingworth and current investor MPM Capital that also included investments from existing shareholders 7 Med Health Ventures, ARCH Venture Partners, F3 Ventures and Fredric Price, Chiasma's Chairman & CEO. [More]
Gamma Knife surgery stops growth of 'World's tallest living human'

Gamma Knife surgery stops growth of 'World's tallest living human'

Sultan Kosen won't be posting new world records for height anymore, but that's just fine with him. The Gamma Knife radiosurgery the 29-year-old Turkish man had in August 2010 has successfully stopped his growth at the height of 8 ft 3 in (251 cm). Mr. Kosen, who suffered the effects of acromegaly, has held the title of "World's Tallest Living Human" since September 2009, when his 8 ft plus stature edged 7 ft 9 in Xiu Xung from China. [More]

World's tallest living man stops growing at 8ft 3 inches

Sultan Kosen has been named the world's tallest living man by Guinness World Records for three consecutive years. In the last three months, the 29-year-old Turkish man has only recently stopped growing thanks to receiving treatment in the U.S. [More]

World's tallest man appears to have stopped growing after treatment at UVA

The world's tallest man appears to have stopped growing following treatment at the University of Virginia Medical Center, earning the medical center a mention in the 2012 Guinness World Records. [More]
Ipsen total revenues increase 5.5% to €1,234.9M for the full year 2011

Ipsen total revenues increase 5.5% to €1,234.9M for the full year 2011

The Board of Directors of Ipsen, chaired by Marc de Garidel, met on 28 February 2012 to review the Group's results for 2011, published today. [More]
New guidelines for the treatment of acromegaly, a serious growth hormone disorder

New guidelines for the treatment of acromegaly, a serious growth hormone disorder

It’s said a lot can happen in seven days. In seven years, a lot has happened in the understanding of acromegaly, a debilitating condition that causes a patient to have too much growth hormone. It’s seven years since the American Association of Clinical Endocrinologists last produced guidelines for the diagnosis and treatment of acromegaly. Their 2004 guidelines were just 13 pages long. Their latest, the 2011 guidelines, have grown – to 44 pages. [More]